Global Genomic Response to Neonatal Screening

View Sample PDF

Copyright: 2015
Pages: 30
Source title: Public Health Genomics and International Wealth Creation
Source Author(s)/Editor(s): E. William Ebomoyi (Chicago State University, USA)
DOI: 10.4018/978-1-4666-8559-8.ch004

Keywords: Medical Information Science Reference / Medicine & Healthcare / Public Health & Healthcare Delivery / Public Health and Welfare

Purchase

View Global Genomic Response to Neonatal Screening on the publisher's website for pricing and purchasing information.

Abstract

In the age of genomic science, neonatal screening for sickle cell anemia involves critical ethical legal, social, and financial implications. The screening for early identification of children most likely to face the complications associated with sickle cell disease was designed to enable parents utilize the state of the art scientific curative care to enable their children to live economically productive lifestyle. However, screening must not be used for discrimination and refusal to insure patient with sickle cell disease. The availability of bone marrow transplant and gene-therapies are clinical options to assist at-risk patients.

The IRMA Community

Research IRM

Global Genomic Response to Neonatal Screening

Purchase

Abstract

Related Content

IRMA Sponsors